Novartis was created in 1996 out of the merger between Sandoz SA and Ciba-Geigy SA. A world leader in the life science field (pharmaceutical industry), Novartis is active in the health care and nutrition sectors. The agribusiness (plant protection and seeds) was spun off in the year 2000. The organisation has 275 branch operations in 142 countries.
Through Emasan SA, the Sandoz Family Foundation holds 3,45% of the share capital of the pharmaceutical company. Disregarding the participation of various of Novartis's own pension funds, this holding makes the Foundation the largest single shareholder in Novartis, just as was formerly the case with Sandoz SA.
The Sandoz Family Foundation supported the Sandoz/Ciba merger decision, while still acknowledging the many and varied human issues resulting therefrom. Conscious of the situation in the international markets and their future development, the Foundation considered the merger to be essential for the organisation's successful long-term survival. Moreover, the merger created the prerequisites needed to make it possible to finance the extremely high research and development costs for drugs and other products. Finally, the merger also honoured the visionary entrepreneurial spirit of Edouard Constant Sandoz, the founder of Sandoz SA.
In its capacity as a long-standing shareholder, the Foundation can identify with the company philosophy that is directed at the development of science in the interests of man and of our environment. As in the past, Novartis will remain one of the Foundation's key positions in view of its commercial and technological legacy and potential.
Through Emasan SA, the Sandoz Family Foundation holds 3,45% of the share capital of the pharmaceutical company.